Overview

ACE-536 Extension Study - Beta Thalassemia

Status:
Completed

Trial end date:
2020-06-18

Target enrollment:

Participant gender:

Summary

Study A536-06 is an open-label extension study for patients previously enrolled in study A536-04 (ClinicalTrials.gov Identifier NCT01749540), to evaluate the long-term safety and tolerability of ACE-536 in adult patients with beta-thalassemia.

Phase:

Phase 2

Details

Lead Sponsor:

Acceleron Pharma Inc.
Acceleron Pharma, Inc.

Treatments:

Luspatercept